The 7 major thrombocytopenia markets reached a value of US$ 3.2 Billion in 2023. Looking forward, the publisher expects the 7MM to reach US$ 5.2 Billion by 2034, exhibiting a growth rate (CAGR) of 5.54% during 2023-2034.
The thrombocytopenia market has been comprehensively analyzed in this report titled "Thrombocytopenia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Thrombocytopenia refers to a health condition characterized by a low platelet count in the blood. Platelets are tiny blood cells that help with blood clotting to prevent excessive bleeding. When the platelet count drops below normal levels, it can lead to abnormal bleeding or bruising, as well as other life-threatening complications. The symptoms of thrombocytopenia can vary depending on the severity of the disease and the underlying cause. In some cases, individuals suffering from this ailment may experience blood in the stool, urine, and vomit; heavy menstrual periods; tiny red or purple dots on the lower legs; nosebleeds; purpura in the forearms; bleeding gums; malaise; fatigue; bruises; rectal bleeding, etc. The diagnosis of the illness is based on the identification of the patient's indications and complete medical history. Various laboratory tests to confirm a diagnosis include a total blood count, kidney function, liver enzymes, vitamin B12 levels, folic acid levels, peripheral blood smear, erythrocyte sedimentation rate, etc. The healthcare provider may also perform a bone marrow biopsy to evaluate the production of platelets.
The escalating utilization of antineoplastic agents, which cause direct myelosuppression, resulting in decreased production or increased destruction of platelets in the body, is primarily driving the thrombocytopenia market. Besides this, the growing prevalence of numerous associated risk factors, such as autoimmune diseases, hemolytic uremic syndrome, pregnancy, bacterial infections, etc., leading to faster breakdown and a shortage of platelets, is also augmenting the market growth. Furthermore, the widespread adoption of corticosteroids, which effectively work by suppressing the immune system, thereby decreasing the antibodies against platelets, and preventing bleeding, is creating a positive outlook for the market. Apart from this, the inflating demand for therapeutic plasma exchange (TPE) as a treatment option for patients with symptomatic and severe thrombocytopenia who fail to respond to traditional regimens is acting as another significant growth-inducing factor. Moreover, the emerging popularity of thrombopoietin receptor agonists, such as avatrombopag, for treating the condition since they increase platelet production by stimulating the formation and maturation of bone marrow cells is expected to drive the thrombocytopenia market in the coming years.
This report provides an exhaustive analysis of the thrombocytopenia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for thrombocytopenia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the thrombocytopenia market in any manner.
The thrombocytopenia market has been comprehensively analyzed in this report titled "Thrombocytopenia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Thrombocytopenia refers to a health condition characterized by a low platelet count in the blood. Platelets are tiny blood cells that help with blood clotting to prevent excessive bleeding. When the platelet count drops below normal levels, it can lead to abnormal bleeding or bruising, as well as other life-threatening complications. The symptoms of thrombocytopenia can vary depending on the severity of the disease and the underlying cause. In some cases, individuals suffering from this ailment may experience blood in the stool, urine, and vomit; heavy menstrual periods; tiny red or purple dots on the lower legs; nosebleeds; purpura in the forearms; bleeding gums; malaise; fatigue; bruises; rectal bleeding, etc. The diagnosis of the illness is based on the identification of the patient's indications and complete medical history. Various laboratory tests to confirm a diagnosis include a total blood count, kidney function, liver enzymes, vitamin B12 levels, folic acid levels, peripheral blood smear, erythrocyte sedimentation rate, etc. The healthcare provider may also perform a bone marrow biopsy to evaluate the production of platelets.
The escalating utilization of antineoplastic agents, which cause direct myelosuppression, resulting in decreased production or increased destruction of platelets in the body, is primarily driving the thrombocytopenia market. Besides this, the growing prevalence of numerous associated risk factors, such as autoimmune diseases, hemolytic uremic syndrome, pregnancy, bacterial infections, etc., leading to faster breakdown and a shortage of platelets, is also augmenting the market growth. Furthermore, the widespread adoption of corticosteroids, which effectively work by suppressing the immune system, thereby decreasing the antibodies against platelets, and preventing bleeding, is creating a positive outlook for the market. Apart from this, the inflating demand for therapeutic plasma exchange (TPE) as a treatment option for patients with symptomatic and severe thrombocytopenia who fail to respond to traditional regimens is acting as another significant growth-inducing factor. Moreover, the emerging popularity of thrombopoietin receptor agonists, such as avatrombopag, for treating the condition since they increase platelet production by stimulating the formation and maturation of bone marrow cells is expected to drive the thrombocytopenia market in the coming years.
This report provides an exhaustive analysis of the thrombocytopenia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for thrombocytopenia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the thrombocytopenia market in any manner.
Time Period of the Study
- Base Year: 2023
- Historical Period: 2018-2023
- Market Forecast: 2024-2034
Countries Covered
- United States
- Germany
- France
- United Kingdom
- Italy
- Spain
- Japan
Analysis Covered Across Each Country
- Historical, current, and future epidemiology scenario
- Historical, current, and future performance of the thrombocytopenia market
- Historical, current, and future performance of various therapeutic categories in the market
- Sales of various drugs across the thrombocytopenia market
Competitive Landscape:
This report also provides a detailed analysis of the current thrombocytopenia marketed drugs and late-stage pipeline drugs.In-Market Drugs
- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
- How has the thrombocytopenia market performed so far and how will it perform in the coming years?
- What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
- What was the country-wise size of the thrombocytopenia market across the seven major markets in 2023 and what will it look like in 2034?
- What is the growth rate of the thrombocytopenia market across the seven major markets and what will be the expected growth over the next ten years?
- What are the key unmet needs in the market?
Epidemiology Insights
- What is the number of prevalent cases (2018-2034) of thrombocytopenia across the seven major markets?
- What is the number of prevalent cases (2018-2034) of thrombocytopenia by age across the seven major markets?
- What is the number of prevalent cases (2018-2034) of thrombocytopenia by gender across the seven major markets?
- How many patients are diagnosed (2018-2034) with thrombocytopenia across the seven major markets?
- What is the size of the thrombocytopenia patient pool (2018-2023) across the seven major markets?
- What would be the forecasted patient pool (2024-2034) across the seven major markets?
- What are the key factors driving the epidemiological trend of thrombocytopenia?
- What will be the growth rate of patients across the seven major markets?
Thrombocytopenia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
- What are the current marketed drugs and what are their market performance?
- What are the key pipeline drugs and how are they expected to perform in the coming years?
- How safe are the current marketed drugs and what are their efficacies?
- How safe are the late-stage pipeline drugs and what are their efficacies?
- What are the current treatment guidelines for thrombocytopenia drugs across the seven major markets?
- Who are the key companies in the market and what are their market shares?
- What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the thrombocytopenia market?
- What are the key regulatory events related to the thrombocytopenia market?
- What is the structure of clinical trial landscape by status related to the thrombocytopenia market?
- What is the structure of clinical trial landscape by phase related to the thrombocytopenia market?
- What is the structure of clinical trial landscape by route of administration related to the thrombocytopenia market?
Table of Contents
1 Preface3 Executive Summary6 Patient Journey9 Thrombocytopenia - Unmet Needs10 Thrombocytopenia - Key Endpoints of Treatment13. Thrombocytopenia - Attribute Analysis of Key Marketed and Pipeline Drugs16 Thrombocytopenia - Recent Events and Inputs From Key Opinion Leaders18 Thrombocytopenia Market - Strategic Recommendations19 Appendix
2 Scope and Methodology
4 Thrombocytopenia - Introduction
5 Thrombocytopenia - Disease Overview
7 Thrombocytopenia - Epidemiology and Patient Population
8 Thrombocytopenia - Treatment Algorithm, Guidelines, and Medical Practices
11 Thrombocytopenia - Marketed Products
12 Thrombocytopenia - Pipeline Drugs
14. Thrombocytopenia - Clinical Trial Landscape
15 Thrombocytopenia - Market Scenario
17 Thrombocytopenia Market - SWOT Analysis
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 129 |
| Published | May 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 3.2 Billion |
| Forecasted Market Value ( USD | $ 5.2 Billion |
| Compound Annual Growth Rate | 4.5% |
| Regions Covered | Global |
